ISSN 0253-2778

CN 34-1054/N

Open AccessOpen Access JUSTC Original Paper

Research and development of biotechnology and drugs

Cite this:
  • Received Date: 28 June 2008
  • Rev Recd Date: 10 August 2008
  • Publish Date: 31 August 2008

Catalog

    [1]
    Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene[J]. Science, 1987,235:177-182.
    [2]
    Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science, 1989, 244:707-712.
    [3]
    Ross J S, Fletcher J A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy[J]. Stem Cell, 1998,16: 413-428.
    [4]
    Hynes N E, Stern D F. The biology of erbB-2/neu/HER-2 and its role in cancer[J]. Biochem Biophys Acta, 1994,1 198:165-184.
    [5]
    王琛,吴强,李昀,等. 表面表位包埋法制备肿瘤表面抗原p185nue/c-erbB-2单克隆抗体及其性质研究[J]. 中国免疫学杂志, 2000,16: 539-546.
    [6]
    Goldenberg M M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody: A novel agent for the treatment of metastatic breast cancer[J]. Clinical Therapeutics, 1999,21:309-318.
    [7]
    Gregory P Adams, Louis M Weiner. Monoclonal antibody therapy of cancer[J]. Nature Biotechnology,2005,23:1 117.
    [8]
    Cheng L, Liu A, Yang J, et al. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185c-erbB-2[J]. Cell Research, 2003,13: 35-48.
    [9]
    Hu S, Zhu Z, Li L, et al. Fine epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for anti-tumor mechanism[J]. Proteins, 2008,70:938-949.

    Article Metrics

    Article views (604) PDF downloads(446)
    Proportional views

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return